NSPR SEC Filings - InspireMD, Inc.- Annual Report, Proxy Statement, Prospectus

Basic Stats

LEI	549300OQ16IJ5DIS5D30
CIK	1433607

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to InspireMD, Inc.

SEC Filings (Chronological Order)

This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.

August 14, 2025	424B3	Up to 16,556,184 Shares of Common Stock Offered by the Selling Stockholders InspireMD, Inc. Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-289292 Up to 16,556,184 Shares of Common Stock Offered by the Selling Stockholders InspireMD, Inc. Common Stock This prospectus relates to the resale, from time to time by the selling stockholders named in this prospectus, or the selling stockholders, of up to 16,556,184 shares of our common stock, which consist of (i) 6,791,380 shar
August 6, 2025	EX-FILING FEES	Calculation of Filing Fee Table Form S-3 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Shares of common Stock, par valu
August 6, 2025	S-3	As filed with the Securities and Exchange Commission on August 6, 2025 As filed with the Securities and Exchange Commission on August 6, 2025 Registration No.
August 5, 2025	EX-99.2	EX-99.2 Exhibit 99.2
August 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2025 InspireMD, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 5, 2025 InspireMD, Inc.
August 5, 2025	EX-99.1	InspireMD Reports Second Quarter 2025 Financial Results Management to host investor conference call today, August 5th, at 8:30am ET --- Exhibit 99.1 InspireMD Reports Second Quarter 2025 Financial Results - Management to host investor conference call today, August 5th, at 8:30am ET - Miami, FL — August 5, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the second quarter and six months ended June 30, 2025. R
August 4, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD
July 31, 2025	EX-10.1	Form of Securities Purchase Agreement Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of July 30, 2025, between InspireMD, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and
July 31, 2025	EX-10.3	Form of Registration Rights Agreement Exhibit 10.3 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of July 30, 2025, between InspireMD, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securitie
July 31, 2025	EX-99.2	InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors Exhibit 99.2 InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors Miami, Florida — July 31, 2025 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Raymond W. Cohen to its Board of Directors. Mr. Cohen has over 40 years of leadership experi
July 31, 2025	EX-10.2	Form of Pre-Funded Warrant Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
July 31, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2025 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 30, 2025 InspireMD, Inc.
July 31, 2025	EX-99.1	InspireMD Announces Combined Financings of $58 Million Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid Stent Exhibit 99.1 InspireMD Announces Combined Financings of $58 Million Proceeds Bolster Balance Sheet to Commercialize Recently FDA Approved Best-In-Class Carotid Stent Miami, Florida — July 31, 2025 – InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the Company has raised approximately $58
July 9, 2025	EX-99.1	InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke Exhibit 99.1 InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke Miami, Florida — July 9, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its
July 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 InspireMD, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numbe
June 24, 2025	EX-99.1	InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke Exhibit 99.1 InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke Miami, Florida — June 24, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (the “Company”) (Nasdaq: NSPR), developer of the CGuard Prime Carotid Stent System for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket application (PMA) ap
June 24, 2025	EX-99.2	Investor Presentation June 2025 Exhibit 99.2
June 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2025 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 23, 2025 InspireMD, Inc.
June 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 InspireMD, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numb
June 13, 2025	EX-99.1	InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke Exhibit 99.1 InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke Miami, Florida — June 13, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the company has received CE Mark approval under the European Medical Dev
June 3, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numbe
June 3, 2025	8-K	Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2025 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numbe
June 3, 2025	EX-99.2	EMPLOYMENT AGREEMENT Exhibit 99.2 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”) is dated as of June 2, 2025, and is entered into by and between Michael Lawless (the “Executive”) and InspireMD, Inc. (the “Company”). The Company and the Executive shall be referred to herein as the “Parties.” RECITALS Whereas, the Company desires to employ the Executive as its Chief Financial Officer on or before June
June 3, 2025	EX-99.1	InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Exhibit 99.1 InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Miami, Florida — June 3, 2025 (GLOBE NEWSWIRE) – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael L
May 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2025 InspireMD, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 9, 2025 InspireMD, Inc.
May 9, 2025	EX-99.1	InspireMD Reports First Quarter 2025 Financial Results Management to host investor conference call today, May 9th, at 8:30am ET — Exhibit 99.1 InspireMD Reports First Quarter 2025 Financial Results — Management to host investor conference call today, May 9th, at 8:30am ET — Miami, FL — May 9, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the first quarter ended
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireM
April 16, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 15, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 8, 2025	CORRESP	InspireMD, Inc. 6303 Waterford District Drive Suite 215 Miami, Florida 33126 InspireMD, Inc. 6303 Waterford District Drive Suite 215 Miami, Florida 33126 April 8, 2025 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InspireMD, Inc. Registration Statement on Form S-3 Filed April 1, 2025 File No. 333-286309 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as a
April 1, 2025	EX-4.3	Form of Subordinated Indenture Exhibit 4.3 INSPIREMD, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 11 Section 103 Form of Documents Delivered to Trustee
April 1, 2025	EX-FILING FEES	Filing Fee Table Exhibit 107 ‌Calculation of Filing Fee Tables ‌Form S-3 (Form Type) ‌InspireMD, Inc.
April 1, 2025	S-3	As filed with the Securities and Exchange Commission on April 1, 2025 As filed with the Securities and Exchange Commission on April 1, 2025 Registration No.
April 1, 2025	EX-4.2	Form of Senior Indenture Exhibit 4.2 INSPIREMD, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 10 Section 103 Form of Documents Delivered to Trustee 10 Se
March 12, 2025	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2025 InspireMD, Inc.
March 12, 2025	EX-10.68	Employment Agreement, dated February 12, 2023, by and between InspireMD, Inc. and Shane Gleason Exhibit 10.68 February 12, 2023 Shane Gleason USA Re: Letter of Intent (“LOI”) for Employment at InspireMD, Inc. Dear Shane, On behalf of InspireMD, Inc. (the “Company”) we are pleased to confirm our offer of employment to you for the General Manager: North America and V.P. Global Marketing reporting to the CEO. Your Start Date is anticipated to be February 20, 2023, which in all cases shall be af
March 12, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as spec
March 12, 2025	EX-99.1	InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results Management to host investor conference call today, March 12th, at 8:30am ET Exhibit 99.1 InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results — Management to host investor conference call today, March 12th, at 8:30am ET — Miami, FL — March 12, 2025 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for th
March 12, 2025	EX-19.1	Insider Trading Policy Exhibit 19.1 POL- 009-11 Rev.: 03 Page: 1 of 12 Insider Trading Policy 1 Purpose This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of InspireMD, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company’s Board of Directors has adopted this Polic
February 7, 2025	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 NSPRexA.htm Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosatind Master Fund L.P. By: Name: Mike McDonald Title: Director, Ros
December 12, 2024	EX-10.1	Ninth Amendment to Employment Agreement, dated December 10, 2024, by and between InspireMD, Inc. and Craig Shore Exhibit 10.1 NINTH AMENDMENT TO EMPLOYMENT AGREEMENT This NINTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), is made and entered into as of December 10, 2024, by and between Craig Shore (the “Executive”) and InspireMD, Inc., a Delaware Corporation (the “Company”) for purposes of amending that certain Amended and Restated Employment Agreement dated as of May 5, 2014, a
December 12, 2024	EX-99.1	InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 Exhibit 99.1 InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 Miami, Florida — December 12, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that Craig Shore, Chief Financial Officer, has decided to retire from the Company after a successor CFO is identified a
December 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 InspireMD, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File
December 9, 2024	EX-99.1	InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) Study represents a significant step forward in Company’s mission to serv Exhibit 99.1 InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) Study represents a significant step forward in Company’s mission to serve the broadest set of physician and patient needs with best-in-class CAS and TCAR solutions Miami, Florida — December 9, 2024 – InspireMD
December 9, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File N
December 4, 2024	SC 13G	NSPR / InspireMD, Inc. / Nantahala Capital Partners Limited Partnership - SC 13G Passive Investment SC 13G 1 tm2430043d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* INSPIREMD, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45779A846 (CUSIP Number) November 27, 2024 (Date of Event which Requires Filing of this Statement) Check the app
November 25, 2024	EX-99.1	InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors Exhibit 99.1 InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors Miami, Florida — November 25, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the appointment of accomplished medical technology executive Scott R. Ward to its Board of D
November 25, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File
November 14, 2024	SC 13G/A	NSPR / InspireMD, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss4113321sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* INSPIREMD, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45779A846 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Che
November 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 InspireMD, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File
November 12, 2024	EX-99.1	InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update - Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. - - Announced approval o Exhibit 99.1 InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update - Submitted a Premarket Approval (PMA) application to the FDA seeking marketing approval of the CGuard Prime carotid stent system in the U.S. - - Announced approval of an IDE application to initiate the CGUARDIANS II pivotal study of the CGuard Prime carotid stent system for use during TCAR procedures
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 Insp
October 28, 2024	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 NSPRexA.htm Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosatind Master Fund L.P. By: Name: Mike McDonald Title: Director, Ros
October 28, 2024	SC 13G/A	NSPR / InspireMD, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindnspr13ga5sep.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 5) Under the Securities Exchange Act of 1934 InspireMD, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45779A846 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate
October 15, 2024	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 9, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Nu
October 15, 2024	EX-10.1	Lease Agreement, dated October 9, 2024, by and between InspireMD, Inc. and ROIB Waterford, LLC Exhibit 10.1 LEASE at WATERFORD Between ROIB WATERFORD, LLC, a Delaware limited liability company (“LANDLORD”) and INSPIREMD, INC., a Delaware corporation (“TENANT”) DATED: October 9, 2024 i LEASE ARTICLE ONE BASIC LEASE PROVISIONS 1.01 BASIC LEASE PROVISIONS - In the event of any conflict between these Basic Lease Provisions and any other Lease provision, such other Lease provision shall control.
October 15, 2024	EX-99.1	InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System Exhibit 99.1 InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System Miami, Florida — October 15, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced the establishment of its global headq
October 7, 2024	EX-99.1	InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System Exhibit 99.1 InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System Miami, Florida — October 7, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the U.S. Food and Drug Administration (FDA) h
October 7, 2024	8-K	Regulation FD Disclosure, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Nu
October 1, 2024	EX-99.4	Form of Inducement Restricted Stock Unit Award Agreement Exhibit 99.4 INDUCEMENT RESTRICTED STOCK UNIT AWARD AGREEMENT INSPIREMD, INC. 1. Award of Restricted Stock Units. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”), InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to [*] (the “Grantee”) an Award, in accordance with Section 8.1(k) of the Plan, for
October 1, 2024	EX-10.1	InspireMD, Inc. 2024 Inducement Plan Exhibit 10.1 InspireMD Inc. 2024 Inducement Plan InspireMD, Inc. 2024 INDUCEMENT PLAN This 2024 Inducement Plan (the “Plan”) provides for the grant of Restricted Stock, Restricted Stock Units and Options to acquire shares of common stock in the capital of InspireMD, Inc. (“Common Stock”) a corporation formed under the laws of the State of Delaware (the “Corporation”). Awards granted under this Pla
October 1, 2024	S-8	As filed with the Securities and Exchange Commission on October 1, 2024 As filed with the Securities and Exchange Commission on October 1, 2024 Registration No.
October 1, 2024	EX-10.3	Form of Inducement Nonqualified Stock Option Agreement Exhibit 10.3 INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Option. Pursuant to the terms of this Inducement Nonqualified Stock Option Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”) grants to [] (the “Optionee”), an option (the “Option” or “Stock Option”) to purchase a total of [] f
October 1, 2024	EX-99.1	InspireMD, Inc. 2024 Inducement Plan Exhibit 99.1 InspireMD Inc. 2024 Inducement Plan InspireMD, Inc. 2024 INDUCEMENT PLAN This 2024 Inducement Plan (the “Plan”) provides for the grant of Restricted Stock, Restricted Stock Units and Options to acquire shares of common stock in the capital of InspireMD, Inc. (“Common Stock”) a corporation formed under the laws of the State of Delaware (the “Corporation”). Awards granted under this Pla
October 1, 2024	EX-10.2	Form of Inducement Restricted Stock Award Agreement Exhibit 10.2 INDUCEMENT RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Award. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to [] (the “Grantee”) this award of restricted shares (this “Restricted Stock Award”). The number of share
October 1, 2024	EX-10.4	Form of Inducement Restricted Stock Unit Award Agreement Exhibit 10.4 INDUCEMENT RESTRICTED STOCK UNIT AWARD AGREEMENT INSPIREMD, INC. 1. Award of Restricted Stock Units. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”), InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to [*] (the “Grantee”) an Award, in accordance with Section 8.1(k) of the Plan, for
October 1, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 30, 2024 InspireMD, Inc.
October 1, 2024	EX-99.3	Form of Inducement Nonqualified Stock Option Agreement Exhibit 99.3 INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Option. Pursuant to the terms of this Inducement Nonqualified Stock Option Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”) grants to [] (the “Optionee”), an option (the “Option” or “Stock Option”) to purchase a total of [] f
October 1, 2024	EX-99.2	Form of Inducement Restricted Stock Award Agreement Exhibit 99.2 INDUCEMENT RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Award. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to [] (the “Grantee”) this award of restricted shares (this “Restricted Stock Award”). The number of share
October 1, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Shares of common Stock, par v
September 16, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 16, 2024 InspireMD, Inc.
September 16, 2024	EX-99.1	InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were firs Exhibit 99.1 InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System PMA based on overwhelmingly positive results from the pivotal C-GUARDIANS clinical study that were first presented at LINC 2024 in May U.S. commercial launch anticipated in H1 2025, if approved Tel Aviv, Israel, and Miami, Florida — Septemb
August 6, 2024	EX-99.1	InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate Exhibit 99.1 InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update - Announced positive outcomes from the C-GUARDIANS IDE clinical trial of the CGuard™ Prime carotid stent system demonstrating a one-year primary endpoint event rate of 1.95%, the lowest for any carotid stent or embolic protection device pivotal trial – - On track to submit a Premarket Approval (PMA) a
August 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 6, 2024 InspireMD, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 6, 2024 InspireMD, Inc.
August 5, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD
July 11, 2024	SC 13G/A	NSPR / InspireMD, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindnspr13ga4jul.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 4) Under the Securities Exchange Act of 1934 InspireMD, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45779A846 (CUSIP Number) June 28, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the r
July 11, 2024	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 NSPRexA.htm Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosatind Master Fund L.P. By: Name: Mike McDonald Title: Director, Ros
July 1, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2024 InspireMD, Inc.
July 1, 2024	EX-99.1	InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Exhibit 99.1 InspireMD Announces Full Exercise of Series H Warrant Tranche for Gross Proceeds of $17.9 Million Series H warrants exercisable following release of positive outcomes results related to one-year follow-up from the Company’s C-GUARDIANS pivotal trial. Participating warrant holders include Marshall Wace, OrbiMed, Rosalind, Nantahala, Soleus, Velan, and certain InspireMD Board members. R
June 13, 2024	EX-99.1	InspireMD Investor Presentation June 2024 Exhibit 99.1
June 13, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2024 InspireMD, Inc.
June 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2024 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2024 InspireMD, Inc.
May 31, 2024	EX-10.1	Equity Distribution Agreement by and between InspireMD, Inc. and Piper Sandler & Co., dated May 31, 2024. Exhibit 10.1 Execution Version INSPIREMD, INC. EQUITY DISTRIBUTION AGREEMENT May 31, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this “Agreement”), InspireMD, Inc., a Delaware corporation (the “Company”), proposes to issue and sell from time to time through Piper Sandler & Co. (the “Agent”
May 31, 2024	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numbe
May 31, 2024	424B5	Piper Sandler The date of this prospectus supplement is May 31, 2024 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-265409 PROSPECTUS SUPPLEMENT (To Prospectus dated June 14, 2022) Up to $17,000,000 Common Stock We have entered into an Equity Distribution Agreement, or the Equity Distribution Agreement, with Piper Sandler & Co., or Piper Sandler, as our sales agent, dated May 31, 2024, relating to the sale of shares of our common stock, $0.001 par value per
May 28, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2024 InspireMD, Inc.
May 28, 2024	EX-99.2	InspireMD LINC 2024 Presentation, May 2024 Exhibit 99.2
May 28, 2024	EX-99.1	InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 Exhibit 99.1 InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024 Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket App
May 17, 2024	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 NSPRexA.htm Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosatind Master Fund L.P. By: Name: Mike McDonald Title: Director, Ros
May 17, 2024	SC 13G/A	NSPR / InspireMD, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindnspr13ga315m.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 3) Under the Securities Exchange Act of 1934 InspireMD, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45779A846 (CUSIP Number) April 24, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
May 14, 2024	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 14, 2024 InspireMD, Inc.
May 14, 2024	EX-99.1	InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-y Exhibit 99.1 InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update - Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 - - Announced that an abstract detailing one-year outcomes from the C-GUARDIANS IDE clinical trial of CGuard™ Prime has been accepted for presentation at LINC 2024, to be held May 28-
May 13, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireM
April 25, 2024	SC 13G/A	NSPR / InspireMD, Inc. / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindnspr13ga2apr24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 2) Under the Securities Exchange Act of 1934 InspireMD, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45779A846 (CUSIP Number) March 31, 2024 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate th
April 25, 2024	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 NSPRexA.htm Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosatind Master Fund L.P. By: Name: Mike McDonald Title: Director, Ros
April 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
April 18, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
April 2, 2024	EX-10.1	Fourth Amendment to Employment Agreement, dated April 1, 2024, by and between InspireMD, Inc. and Marvin Slosman Exhibit 10.1 FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), dated as of April 1, 2024, by and between Marvin Slosman (the “Executive”) and InspireMD, Inc. (the “Company”). WHEREAS, the Company and Executive are parties to an Employment Agreement dated as of December 9, 2019, as amended by those amendments dated as of December 31, 2019, No
April 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 2, 2024 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 2, 2024 InspireMD, Inc.
April 2, 2024	EX-10.2	Eighth Amendment to Employment Agreement, dated April 1, 2024, by and between InspireMD, Inc. and Craig Shore Exhibit 10.2 EXECUTION VERSION EIGHTH AMENDMENT TO EMPLOYMENT AGREEMENT This EIGHTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”), is made and entered into as of April 1, 2024, by and between Craig Shore (the “Executive”) and InspireMD, Inc., a Delaware Corporation (the “Company”) for purposes of amending that certain Amended and Restated Employment Agreement dated as o
March 26, 2024	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 26, 2024 InspireMD, Inc.
March 26, 2024	EX-99.1	InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 Exhibit 99.1 InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024 Tel Aviv, Israel, and Miami, Florida — March 26, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abst
March 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2024 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2024 InspireMD, Inc.
March 6, 2024	EX-99.1	InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the C Exhibit 99.1 InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update - Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company’s ongoing U.S. Investigational Device Exemption (IDE) clinical trial, C-GUARDIANS, designed to support U.S. approval of CGuard Pri
March 5, 2024	EX-10.62	Fourth Amendment to Employment Agreement, dated August 14, 2020, by and between InspireMD, Inc. and Craig Shore Exhibit 10.62 IN WITNESS WHEREOF, the parties have executed this Fourth Amendment to Amended and Restated Employment Agreement as of the Amendment Effective Date. THE COMPANY: INSPIREMD, INC. By: /s/ Marvin Slosman Name: Marvin Slosman Title Chief Executive Officer EXECUTIVE: /s/ Craig Shore Craig Shore August 14, 2020
March 5, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as spec
March 5, 2024	EX-97.1	InspireMD, Inc. Executive Officer Clawback Policy Exhibit 97.1 InspireMD, Inc. Executive Officer Clawback Policy I. Purpose This Executive Officer Clawback Policy describes the circumstances under which Covered Persons of InspireMD, Inc. and any of its direct or indirect subsidiaries (the “Company”) will be required to repay or return Erroneously-Awarded Compensation to the Company. This Policy and any terms used in this Policy shall be construed
March 5, 2024	EX-4.1	Exhibit 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 5, 2024, InspireMD, Inc., a Delaware corporation (“we,” “our” and the “Company”) has one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value $0.0001 per share. The following description of such security is i
February 14, 2024	SC 13G	DE:II2Q / InspireMD Inc / Nantahala Capital Management, LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* InspireMD, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45779A846 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pu
February 14, 2024	EX-99.A BD-DIR-RESOL	Joint Filing Agreement EX-99.A BD-DIR-RESOL 2 NSPRexA14Feb24.htm Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc. is filed jointly, on behalf of each of them. Rosalind Advisors, Inc. By: Name: Steven Salamon Title: President Rosatind Master Fund L.P. By: Name: Mike McDonald Title: Direct
February 14, 2024	SC 13G	DE:II2Q / InspireMD Inc / ORBIMED ADVISORS LLC - SC 13G Passive Investment SC 13G 1 ss3005768sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INSPIREMD, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45779A846 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design
February 14, 2024	SC 13G/A	DE:II2Q / InspireMD Inc / Rosalind Advisors, Inc. Passive Investment SC 13G/A 1 rosalindnspr13ga114fec24.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Amendment No. 1) Under the Securities Exchange Act of 1934 InspireMD, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45779A846 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designa
February 14, 2024	EX-99.A	JOINT FILING AGREEMENT EX-99.A 2 ss3005768ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that this Statement on Schedule 13G, dated December 31, 2023 (this “Schedule 13G”), with respect to the Common Stock, par value $0.0001 per share, of InspireMD, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities
January 31, 2024	EX-99.1	InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework Exhibit 99.1 InspireMD Receives CE Mark Recertification Under EU’s New Medical Device Regulation (MDR) Regulatory Framework Tel Aviv, Israel, and Miami, FL — January 31, 2024 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today announced that it has received CE Mark recertification under the European Union’s ne
January 31, 2024	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 31, 2024 InspireMD, Inc.
January 2, 2024	EX-99.3	Form of Inducement Nonqualified Stock Option Agreement Exhibit 99.3 INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Option. Pursuant to the terms of this Inducement Nonqualified Stock Option Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”) grants to Pete Ligotti (the “Optionee”), an option (the “Option” or “Stock Option”) to purchase a tot
January 2, 2024	EX-99.2	Form of Inducement Restricted Stock Award Agreement Exhibit 99.2 INDUCEMENT RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Award. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to Pete Ligotti (the “Grantee”) this award of restricted shares (this “Restricted Stock Award”). The numbe
January 2, 2024	S-8	As filed with the Securities and Exchange Commission on January 2, 2024 As filed with the Securities and Exchange Commission on January 2, 2024 Registration No.
January 2, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Shares of common Stock, par valu
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2023 InspireMD, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2023 InspireMD, Inc.
December 20, 2023	EX-99.1	InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the tr Exhibit 99.1 InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuardTM Neuroprotection System Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of stroke Tel Aviv, Israel, and Miami, Florida — December 20, 2023 – InspireMD (Nasd
November 27, 2023	EX-99.1	InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions Study to enroll 15 acute stroke patients across three U.S. sites. Exhibit 99.1 InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions Study to enroll 15 acute stroke patients across three U.S. sites. Tel Aviv, Israel, and Miami, Florida — November 27, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System
November 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 27, 2023 InspireMD, Inc. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 27, 2023 InspireMD, Inc.
November 6, 2023	EX-99.1	InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update - Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse e Exhibit 99.1 InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update - Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) – - Announced s
November 6, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 Insp
November 6, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2023 InspireMD, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2023 InspireMD, Inc.
November 1, 2023	EX-99.1	InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure. Exhibit 99.1 InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure. Tel Aviv, Israel, and Miami, Florida — November 1, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) fo
November 1, 2023	EX-99.2	InspireMD VIVA23 Presentation, November 2023 Exhibit 99.2
November 1, 2023	8-K	Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2023 InspireMD, Inc.
October 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 12, 2023 InspireMD, Inc. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 12, 2023 InspireMD, Inc.
October 12, 2023	EX-99.1	InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients Provides additional treatment options for patients and treating physicians; likel Exhibit 99.1 InspireMD Supports CMS’ Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to min
October 6, 2023	S-8	As filed with the Securities and Exchange Commission on October 6, 2023 As filed with the Securities and Exchange Commission on October 6, 2023 Registration No.
October 6, 2023	EX-99.3	Form of Inducement Nonqualified Stock Option Agreement Exhibit 99.3 INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Option. Pursuant to the terms of this Inducement Nonqualified Stock Option Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”) grants to Patrick Verta (the “Optionee”), an option (the “Option” or “Stock Option”) to purchase a to
October 6, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 5, 2023 InspireMD, Inc.
October 6, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Shares of common Stock, par valu
October 6, 2023	EX-99.2	Form of Inducement Restricted Stock Award Agreement Exhibit 99.2 INDUCEMENT RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Award. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to Patrick Verta (the “Grantee”) this award of restricted shares (this “Restricted Stock Award”). The numb
September 13, 2023	8-K	Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 13, 2023 InspireMD, Inc.
September 13, 2023	EX-3.1	Certificate of Amendment to Amended and Restated Certificate of Incorporation of InspireMD, Inc. (incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed on September 13, 2023) Exhibit 3.1 CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF INSPIREMD, INC. InspireMD, Inc., a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. The certificate of incorporation of the Corporation is hereby amended by deleting ARTICLE EIGHTH thereof in its entirety and inserting the follo
August 31, 2023	EX-99.1	InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 Exhibit 99.1 InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23 Tel Aviv, Israel, and Miami, Florida — August 31, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that an abstract detailing
August 31, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2023 InspireMD, Inc. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2023 InspireMD, Inc.
August 8, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 8, 2023 InspireMD, Inc.
August 8, 2023	EX-99.1	InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on Exhibit 99.1 InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and secondary endpoints and, if successful, submit PMA application in H2 2024 – - Generated Q2 2023 CGuard EPS
August 7, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD
July 28, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
July 28, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State
July 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 20, 2023 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 20, 2023 InspireMD, Inc.
July 18, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
June 26, 2023	EX-99.1	InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-huma Exhibit 99.1 InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company anticipates study results and Premarket Approval (PMA) submission i
June 26, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2023 InspireMD, Inc. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2023 InspireMD, Inc.
June 16, 2023	EX-1	Exhibit 1 – Form of Section 102 Capital Gain Restricted Stock Award Agreement Exhibit 1 SECTION 102 CAPITAL GAIN RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC.
June 16, 2023	SC 13D	DE:II2Q / InspireMD Inc / Shore Craig Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D InspireMD, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45779A846 (CUSIP Number) Craig Shore c/o InspireMD, Inc. 4 Menorat Hamaor. St. Tel Aviv, Israel 6744832 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 8, 2
June 16, 2023	EX-2	Exhibit 2 – Form of Irrevocable Proxy and Power of Attorney Agreement Exhibit 2 IRREVOCABLE PROXY AND POWER OF ATTORNEY AGREEMENT This IRREVOCABLE PROXY AND POWER OF ATTORNEY AGREEMENT, dated as of May 17, 2023 (as the same may be amended from time to time, this “Agreement”), by and among InspireMD Inc.
June 8, 2023	EX-99.A BD-DIR-RESOL	Joint Filing Agreement Exhibit A Joint Filing Agreement Tje undersigned hereby agree that this Statement on Schedule 13G with respect to the beneficial ownership of shares of Common Stocr of InspireMD, Inc.
June 8, 2023	SC 13G	DE:II2Q / InspireMD Inc / Rosalind Advisors, Inc. - INSPIREMD 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 InspireMD, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 45779A846 (CUSIP Number) June 1, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ¨ Rule 13d-
June 2, 2023	424B3	Up to 77,484,492 Shares of Common Stock Offered by the Selling Stockholders InspireMD, Inc. Common Stock PROSPECTUS Filed pursuant to Rule 424(b)(3) Registration No. 333-272149 Up to 77,484,492 Shares of Common Stock Offered by the Selling Stockholders InspireMD, Inc. Common Stock This prospectus relates to the resale, from time to time by the selling stockholders named in this prospectus, or the selling stockholders, of up to 77,484,492 shares of our common stock, which consist of (i) 10,266,270 sha
May 31, 2023	CORRESP	InspireMD, Inc. 4 Menorat Hamaor. St. Tel Aviv, Israel 6744832 InspireMD, Inc. 4 Menorat Hamaor. St. Tel Aviv, Israel 6744832 May 31, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 RE: InspireMD, Inc. (CIK 0001433607) Registration Statement No. 333-272149 on Form S-3 (the “Registration Statement”) Ladies and Gentlemen: InspireMD, Inc. (the “Registrant”) hereby requests acceleration of
May 24, 2023	SC 13G	DE:II2Q / InspireMD Inc / Soleus Private Equity Fund III, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* InspireMD, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 45779A846 (CUSIP Number) May 16, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
May 24, 2023	EX-99.A	JOINT FILING AGREEMENT EX-99.A EXHIBIT A JOINT FILING AGREEMENT Soleus Private Equity Fund III, L.P., a Delaware limited partnership, Soleus Private Equity GP III, LLC, a Delaware limited liability company, Soleus PE GP III, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendment
May 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 23, 2023 InspireMD, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 23, 2023 InspireMD, Inc.
May 23, 2023	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 ex107.htm Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Share
May 23, 2023	EX-99.1	InspireMD Investor Presentation May 2023 EX-99.1 2 ex99-1.htm Exhibit 99.1
May 23, 2023	S-3	As filed with the Securities and Exchange Commission on May 23, 2023 As filed with the Securities and Exchange Commission on May 23, 2023 Registration No.
May 22, 2023	SC 13G	DE:II2Q / InspireMD Inc / Marshall Wace North America L.P. - INSPIREMD, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* InspireMD, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 45779A846 (CUSIP Number) May 12, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
May 17, 2023	EX-99.3	Form of Inducement Nonqualified Stock Option Agreement EX-99.3 9 ex99-3.htm Exhibit 99.3 INDUCEMENT NONQUALIFIED STOCK OPTION AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Option. Pursuant to the terms of this Inducement Nonqualified Stock Option Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”) grants to Shane Gleason (the “Optionee”), an option (the “Option” or “Stock Opti
May 17, 2023	S-8	As filed with the Securities and Exchange Commission on May 17, 2023 As filed with the Securities and Exchange Commission on May 17, 2023 Registration No.
May 17, 2023	EX-99.2	Form of Inducement Restricted Stock Award Agreement Exhibit 99.2 INDUCEMENT RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 1. Grant of Award. Pursuant to the terms of this Inducement Restricted Stock Award Agreement (this “Agreement”) InspireMD, Inc., a Delaware corporation (the “Company”; together with its Subsidiaries, the “Group”), grants to Shane Gleason (the “Grantee”) this award of restricted shares (this “Restricted Stock Award”). The numb
May 17, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Shares of common Stock, par valu
May 16, 2023	EX-99.1	InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an Exhibit 99.1 InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update - Completed transformational private placement for up to $113.6 million, including $42.2 million upfront - - Generated Q1 2023 CGuard EPS revenue of $1.2 million, an increase of 6.7% over Q1 2022 despite the temporary expiration of the Company’s CE Mark certification until mid-March – - Resumed shipmen
May 16, 2023	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 16, 2023 InspireMD, Inc.
May 15, 2023	EX-10.7	Form of Registration Rights Agreement dated as of May 12, 2023 between the Company and purchaser identified therein (incorporated by reference to Exhibit 10.7 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.7 Execution Version REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of May 12, 2023, between InspireMD, Inc., a Delaware corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities
May 15, 2023	EX-99.1	InspireMD Announces Private Placement of Up to $113.6 Million Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 Exhibit 99.1 InspireMD Announces Private Placement of Up to $113.6 Million Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members $42.2 million financing upfront with up to an additional $71.4 million tied to exercise of milestone-driven warrants Tel Aviv, Israel and Miami, Florida — May 15, 2023 – InspireMD, Inc. (Nasdaq: NSPR)
May 15, 2023	EX-10.4	Form of Series I Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.4 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 15, 2023	10-Q	Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireM
May 15, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2023 InspireMD, Inc. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 12, 2023 InspireMD, Inc.
May 15, 2023	EX-10.1	Form of Securities Purchase Agreement dated as of May 12, 2023 between the Company and purchaser identified therein (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 12, 2023, between InspireMD, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and c
May 15, 2023	EX-10.6	Form of Series K Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.6 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 15, 2023	EX-10.5	Form of Series J Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 15, 2023	EX-10.3	Form of Series H Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
May 15, 2023	EX-10.2	Form of Pre-Funded Warrant dated May 15, 2023 (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K dated May 15, 2023) Exhibit 10.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST
March 30, 2023	EX-10.66	Employment Agreement, dated November 2, 2020, by and between the Company and Andrea Tommasoli (incorporated by reference to Exhibit 10.66 to the Annual Report on Form 10-K filed on March 30, 2023) Exhibit 10.66
March 30, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2023 InspireMD, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 30, 2023 InspireMD, Inc.
March 30, 2023	EX-10.65	Seventh Amendment to Employment Agreement, dated January 18, 2023, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.65 to the Annual Report on Form 10-K filed on March 30, 2023) Exhibit 10.65 SEVENTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SEVENTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered as of this 18th day of January 2023 (the “Amendment Effective Date”) by and between InspireMD, Inc., a Delaware corporation (the “Company”), and Craig Shore (the “Executive”; together with the Company, the “Parties”)
March 30, 2023	EX-4.1	Exhibit 4.1 Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 30, 2023, InspireMD, Inc., a Delaware corporation (“we,” “our” and the “Company”) has one class of security registered under Section 12 of the Securities Exchange Act of 1934, as amended: common stock, par value $0.0001 per share. The following description of such security is
March 30, 2023	EX-99.1	InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 – - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Me Exhibit 99.1 InspireMD Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - 2022 CGuard EPS revenue of $5.1 million increased 18.9% over 2021 – - Resumed shipments of CGuard EPS to CE Mark territories under the pre-existing Medical Device Directive (MDD) regulatory framework; Company anticipates re-certification under new Medical Device Regulation (MRD) framewo
March 30, 2023	10-K	Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as spec
March 30, 2023	EX-10.64	Third Amendment to Employment Agreement, dated January 5, 2023, by and between InspireMD, Inc. and Marvin Slosman (incorporated by reference to Exhibit 10.64 to the Annual Report on Form 10-K filed on March 30, 2023) Exhibit 10.64 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (this “Amendment”), dated as of January 5, 2023 by and between Marvin Slosman (the “Executive”) and InspireMD, Inc. (the “Company”). WHEREAS, the Company and Executive are parties to an Employment Agreement dated as of December 9, 2019, as amended by those amendments dated as of December 31, 2019 and
March 20, 2023	EX-99.1	InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Int Exhibit 99.1 InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer Mr. Tommasoli formerly served as the Company’s Senior Vice President of Global Sales & Marketing since 2020 and has significant prior commercial leadership experience at Integra LifeSciences and St. Jude Medical Tel Aviv, Israel — March 20, 2023 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embol
March 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2023 InspireMD, Inc. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 15, 2023 InspireMD, Inc.
November 8, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2022 InspireMD, Inc.
November 8, 2022	EX-99.1	InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update - Generated 38.8% growth in CGuard™ revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on tra Exhibit 99.1 InspireMD Reports Third Quarter 2022 Financial Results and Provides Business Update - Generated 38.8% growth in CGuard™ revenue year-over-year - - Continued enrollment in the C-Guardian US IDE trial, with 24 sites currently enrolling patients; on track to complete enrollment by approximately end of Q1 2023 - - Announced strategic partnership with NAMSA, a med tech contract research or
November 7, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 Insp
September 1, 2022	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 31, 2022 InspireMD, Inc.
August 11, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 9, 2022 InspireMD, Inc.
August 11, 2022	EX-99.1	InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update - Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case t Exhibit 99.1 InspireMD Reports Second Quarter 2022 Financial Results and Provides Business Update - Generated 47.8% growth in CGuard™ revenue year-over-year - - Delivered several presentations at LINC 2022 featuring CGuard™ EPS, including a successful live case transmission - - Announced that endovascular pioneer Dr. Juan Parodi has agreed to act as strategic advisor to the company - — Management
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD
July 5, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
July 5, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
June 13, 2022	CORRESP	InspireMD, Inc. 4 Menorat Hamaor St. Tel Aviv, 674483 June 13, 2022 InspireMD, Inc. 4 Menorat Hamaor St. Tel Aviv, 674483 Israel June 13, 2022 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: InspireMD, Inc. Registration Statement on Form S-3 File No. 333-265409 VIA EDGAR Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, InspireMD, Inc. (the ?Registrant?) hereby
June 3, 2022	S-3	As filed with the Securities and Exchange Commission on June 3, 2022 As filed with the Securities and Exchange Commission on June 3, 2022 Registration No.
June 3, 2022	8-K	Entry into a Material Definitive Agreement, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2022 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numbe
June 3, 2022	EX-1.2	Sales Agreement by and between InspireMD, Inc. and A.G.P./Alliance Global Partners, dated June 3, 2022 (incorporated by reference to Exhibit 1.2 of the Registration Statement on Form S-3 as filed on June 3, 2022). Exhibit 1.2 INSPIREMD, INC. Common Stock SALES AGREEMENT June 3, 2022 A.G.P./Alliance Global Partners 590 Madison Avenue, 28th Floor New York, NY 10022 Ladies and Gentlemen: InspireMD, Inc., a Delaware corporation (the ?Company?), confirms its agreement (this ?Agreement?) with A.G.P./Alliance Global Partners (the ?Sales Agent?), as follows: 1. Issuance and Sale of Shares. The Company agrees that,
June 3, 2022	EX-4.3	Form of Subordinated Indenture Exhibit 4.3 INSPIREMD, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SUBORDINATED DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 11 Section 103 Form of Documents Delivered to Trustee
June 3, 2022	EX-4.2	Form of Senior Indenture Exhibit 4.2 INSPIREMD, INC. TO [], as Trustee GUARANTEED TO THE EXTENT SET FORTH HEREIN BY THE GUARANTORS NAMED HEREIN INDENTURE Dated as of [], 20[] SENIOR DEBT SECURITIES TABLE OF CONTENTS Page Article One Definitions and Other Provisions of General Application 1 Section 101 Definitions 1 Section 102 Compliance Certificates and Opinions 10 Section 103 Form of Documents Delivered to Trustee 10 Se
June 3, 2022	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) InspireMD, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee
May 20, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 20, 2022 InspireMD, Inc.
May 10, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 10, 2022 InspireMD, Inc.
May 10, 2022	EX-99.1	InspireMD Reports First Quarter 2022 Financial Results and Business Update - 20% growth in CGuard™ revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Dis Exhibit 99.1 InspireMD Reports First Quarter 2022 Financial Results and Business Update - 20% growth in CGuard? revenue Year-over-Year - - C-Guardian FDA IDE Trial Completes First European Enrollment - - Held Key Opinion Leader (KOL) Webinar on Carotid Artery Disease Management and Stroke Prevention, highlighting CGuard? clinical advantages - - European logistics hub established with BOMI Group ?f
May 9, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireM
March 8, 2022	EX-99.1	InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results - CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year - - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Establ Exhibit 99.1 InspireMD Reports Fourth Quarter and Year-End 2021 Financial Results - CGuard™ Revenue Generated 87.5% growth over Q4’20 and 55.9% Year-over-Year - - Published CGuard Clinical trial results in Journals of the American College of Cardiology - - Established Reimbursement Approval for CGuard from the French National Authority - - CGuard Included as Carotid Stent Treatment Option in Natio
March 8, 2022	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2022 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 001-35731 26-2123838 (Commission File Numb
March 7, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 COMMISSION FILE NUMBER: 001-35731 InspireMD, Inc. (Exact name of registrant as spec
March 7, 2022	EX-10.57	Form of Nonqualified Stock Option Agreement for U.S. directors under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.57 to the Annual Report on Form 10-K filed on March 7, 2022) EX-10.57 8 ex10-57.htm Exhibit 10.57 NONQUALIFIED STOCK OPTION AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Option. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the “Plan”) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (collectively, the “Group”), the Company grants
March 7, 2022	EX-10.55	Form of Nonqualified Stock Option Agreement for consultants under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.55 to the Annual Report on Form 10-K filed on March 7, 2022) Exhibit 10.55 NONQUALIFIED STOCK OPTION AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION 1. Grant of Option. Pursuant to the InspireMD, Inc. 2021 Equity Compensation Plan (the ?Plan?) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries (collectively, the ?Group?), the Company grants to [*] (the ?Participant?),
March 7, 2022	EX-10.59	Form of Restricted Stock Award Agreement for U.S. directors under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.59 to the Annual Report on Form 10-K filed on March 7, 2022) Exhibit 10.59 RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Award. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the ?Plan?) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries (collectively, the ?Group?), [*] (the ?Participant?) has been granted a Re
March 7, 2022	EX-10.61	Form of Restricted Stock Award Agreement for European employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.61 to the Annual Report on Form 10-K filed on March 7, 2022) Exhibit 10.61 RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Award. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the ?Plan?) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries (collectively, the ?Group?), [*] (the ?Participant?) has been granted a Re
March 7, 2022	EX-10.58	Form of Restricted Stock Award Agreement for U.S. employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.58 to the Annual Report on Form 10-K filed on March 7, 2022) EX-10.58 9 ex10-58.htm Exhibit 10.58 RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Award. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the “Plan”) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (collectively, the “Group”), [*] (the “Participant”
March 7, 2022	EX-4.1	Description of Securities Exhibit 4.1 DESCRIPTION OF SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of March 7, 2022, InspireMD, Inc., a Delaware corporation (?we,? ?our? and the ?Company?) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) common stock, par value $0.0001 per share; and (ii) Series B Warrants, with each w
March 7, 2022	EX-10.53	Form of Nonqualified Stock Option Agreement for U.S. employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.53 to the Annual Report on Form 10-K filed on March 7, 2022) Exhibit 10.53 NONQUALIFIED STOCK OPTION AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Option. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the ?Plan?) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries (collectively, the ?Group?), the Company grants to [*] (the ?Participa
March 7, 2022	EX-10.56	Form of Nonqualified Stock Option Agreement for Israeli employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.56 to the Annual Report on Form 10-K filed on March 7, 2022) EX-10.56 7 ex10-56.htm Exhibit 10.56 SECTION 102 CAPITAL GAIN STOCK OPTION AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION 1. Grant of Option. Pursuant to the InspireMD, Inc. 2021 Equity Compensation Plan (the “Plan”) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (collectively, the “Group”), the Company
March 7, 2022	EX-10.60	Form of Restricted Stock Award Agreement for Israeli employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.60 to the Annual Report on Form 10-K filed on March 7, 2022) Exhibit 10.60 SECTION 102 CAPITAL GAIN RESTRICTED STOCK AWARD AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Award. Pursuant to the InspireMD, Inc. 2021 Equity Compensation Plan (the ?Plan?) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the ?Company?), and its Subsidiaries (collectively, the ?Group?), [*] (the ?Participan
March 7, 2022	EX-10.51	Sixth Amendment to Employment Agreement, dated January 17, 2022, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.51 to the Annual Report on Form 10-K filed on March 7, 2022) EX-10.51 3 ex10-51.htm Exhibit 10.51 SIXTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This SIXTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this “Amendment”) is made and entered as of this 17 day of January 2022 (the “Amendment Effective Date”) by and between InspireMD, Inc., a Delaware corporation (the “Company”), and Craig Shore (the “Executive”; together with the Compan
March 7, 2022	EX-10.62	Form of Restricted Stock Unit Award Agreement under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.62 to the Annual Report on Form 10-K filed on March 7, 2022) Exhibit 10.62 RESTRICTED STOCK UNIT AWARD AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Award of Restricted Stock Units. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the ?Plan?) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the ?Company?) and its Subsidiaries (collectively, the ?Group?), [*] (the ?Participant?)
March 7, 2022	EX-10.54	Form of Nonqualified Stock Option Agreement for European employees under the 2021 Equity Incentive Plan (incorporated by reference to Exhibit 10.54 to the Annual Report on Form 10-K filed on March 7, 2022) EX-10.54 5 ex10-54.htm Exhibit 10.54 STOCK OPTION AGREEMENT INSPIREMD, INC. 2021 EQUITY COMPENSATION PLAN 1. Grant of Option. Pursuant to the InspireMD, Inc. 2021 EQUITY COMPENSATION PLAN (the “Plan”) for key Employees, key Contractors, and Outside Directors of InspireMD, Inc., a Delaware corporation (the “Company”), and its Subsidiaries (collectively, the “Group”), the Company grants to [*] (the
February 28, 2022	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2022 InspireMD, Inc.
February 28, 2022	EX-99.1	InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application - CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical t EX-99.1 2 ex99-1.htm Exhibit 99.1 InspireMD Announces the Inclusion of its CGuard Carotid Stent in CREST-2 Trial Following FDA Approval of the Investigational Device Exemption Supplement Application - CGuard™ Carotid Stent will now be a treatment option in the stenting plus medical therapy arm of the trial for patients - - CREST-2 Trial is sponsored by the National Institute of Neurological Disord
February 11, 2022	SC 13G/A	DE:II2Q / InspireMD Inc / Lind Global Macro Fund LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* InspireMD, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share. (Title of Class of Securities) 45779A846 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule
January 10, 2022	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 10, 2022 InspireMD, Inc.
January 10, 2022	EX-99.1	Slide Presentation of InspireMD, Inc. dated January 10, 2022 Exhibit 99.1
December 7, 2021	8-K	Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 7, 2021 InspireMD, Inc.
December 7, 2021	EX-99.1	Slide Presentation of InspireMD, Inc. dated December 7, 2021 EX-99.1 2 ex99-1.htm Exhibit 99.1
November 9, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 9, 2021 InspireMD, Inc.
November 9, 2021	EX-99.1	InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update -CGuard™ sales generated 24% YoY revenue growth- -CGuard™ EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement Exhibit 99.1 InspireMD Reports Third Quarter 2021 Financial Results and Provides Corporate Update -CGuard? sales generated 24% YoY revenue growth- -CGuard? EPS received a positive opinion from the French National Authority for Health (HAS) regarding reimbursement in France- - $37.1 million in cash, cash equivalents and short-term bank deposits as of September 30, 2021, provides runway into first h
November 8, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 Insp
November 8, 2021	EX-10.1	First Amendment to Employment Agreement, dated November 8, 2021, by and between InspireMD, Inc. and Marvin Slosman (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on November 8, 2021). Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (this ?Amendment?) is made and entered as of this 8th day of November, 2021 (the ?Amendment Effective Date?) by and between InspireMD, Inc., a Delaware corporation (the ?Company?), and Martin Slosman (the ?Executive?; together with the Company, the ?Parties?) for purposes of amending that certain Empl
November 8, 2021	EX-10.2	Fifth Amendment to Employment Agreement, dated November 4, 2021, by and between InspireMD, Inc. and Craig Shore (incorporated by reference to Exhibit 10.2 to the Quarterly Report on Form 10-Q filed on November 8, 2021). Exhibit 10.2 FIFTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT This FIFTH AMENDMENT TO AMENDED AND RESTATED EMPLOYMENT AGREEMENT (this ?Amendment?) is made and entered as of this 4th day of November, 2021 (the ?Amendment Effective Date?) by and between InspireMD, Inc., a Delaware corporation (the ?Company?), and Craig Shore (the ?Executive?; together with the Company, the ?Parties?) for
November 4, 2021	EX-99.1	InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions EX-99.1 2 ex99-1.htm Exhibit 99.1 InspireMD Announces Publication of 12-Month Results of CGuard™ EPS SIBERIA Trial in Journals of the American College of Cardiology: Cardiovascular Interventions Tel Aviv, Israel— November 3, 2021 – InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease
November 4, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report: November 4, 2021 InspireMD, Inc.
October 13, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report: October 13, 2021 InspireMD, Inc.
October 13, 2021	EX-99.1	InspireMD Receives Reimbursement Approval for CGuard™ Embolic Prevention System from the French National Authority for Health Exhibit 99.1 InspireMD Receives Reimbursement Approval for CGuard? Embolic Prevention System from the French National Authority for Health Tel Aviv, Israel? October 13, 2021 - InspireMD, Inc. (Nasdaq: NSPR), a global developer of the CGuard? Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announced that its CGuard EPS sten
October 13, 2021	S-8	As filed with the Securities and Exchange Commission on October13, 2021 As filed with the Securities and Exchange Commission on October13, 2021 Registration No.
September 30, 2021	8-K	Submission of Matters to a Vote of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of report (Date of Earliest Event Reported): September 30, 2021 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 001-35731 26-2123838 (Commiss
August 12, 2021	DEF 14A	2021 Equity Compensation Plan (Incorporated by reference to Annex A to the registrant’s Proxy Statement on Schedule 14A filed with the Commission on August 12, 2021). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
August 10, 2021	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2021 InspireMD, Inc.
August 10, 2021	EX-99.1	InspireMD Announces Strong Second Quarter 2021 Financial Results Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET Exhibit 99.1 InspireMD Announces Strong Second Quarter 2021 Financial Results Revenue rebound, strong procedural recovery Management to host investor conference call today, August 10, 2021, at 8:30am ET Tel Aviv, Israel? August 10, 2021 ? InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard? Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery D
August 9, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35731 InspireMD
August 9, 2021	EX-10.1	Seventh Amendment to the InspireMD, Inc. 2013 Long-Term Incentive Plan (incorporated by reference to Exhibit 10.1 to the Quarterly Report on Form 10-Q filed on August 9, 2021) Exhibit 10.1 SEVENTH AMENDMENT TO THE INSPIREMD, INC. 2013 LONG-TERM INCENTIVE PLAN This SEVENTH AMENDMENT TO THE INSPIREMD, INC. 2013 LONG-TERM INCENTIVE PLAN (this ?Amendment?), dated as of June 20, 2021 (the ?Effective Date?) is made and entered into by InspireMD, Inc., a Delaware corporation (the ?Company?). Terms used in this Amendment with initial capital letters that are not otherwise defin
July 26, 2021	EX-99.1	InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS EX-99.1 2 ex99-1.htm Exhibit 99.1 InspireMD Enrolls and Treats First Patients at Ballad Health System in U.S. Registration C-Guardian Clinical Trial of CGuard EPS Tel Aviv, Israel— July 23, 2021 - InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease (CAD) and stroke prevention, today announces the initiati
July 26, 2021	8-K	Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report: July 26, 2021 InspireMD, Inc.
June 29, 2021	EX-3.2	Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to Current Report on Form 8-K filed with the Securities and Exchange Commission on June 29, 2021) Exhibit 3.2 INSPIREMD, INC. AMENDED AND RESTATED BYLAWS ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. (1) An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Directors shall eac
June 29, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2021 InspireMD, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35731 26-2123838 (State or other jurisdiction of incorporation) (Commission File Numb

NSPR / InspireMD, Inc. - SEC Filings, Annual Report, Proxy Statement

Basic Stats

SEC Filings

SEC Filings (Chronological Order)

Other Listings